Disorders of sex development (DSD) are a group of rare conditions that usually present in early infancy with an abnormality of the external and/or internal reproductive organs and commonly arise because of a disorder of gonadal, adrenal, or hormonal function. Although the overall birth prevalence of conditions associated with DSD may be as high as 1 in 300 ([@B1]), individual pathophysiological conditions are much rarer, limiting the study of their etiology and prognosis.

Although enormous advances in our knowledge have been achieved over the last decade, the genetic etiology in most cases of DSD remains unclear ([@B2], [@B3]). Furthermore, our understanding of the basis of the genetic modifiers of monogenic DSD remains in its infancy. Mammalian sex development, which is already known to be closely linked to the development of the urological system ([@B4]), occurs at critical stages of embryonic and fetal development. These windows may also be important for the development of other organs as illustrated by a number of known conditions associated with DSD ([@B5][@B6][@B7]). High-throughput gene sequencing technology has the potential to identify a number of attributable genetic variations but understanding the link between these variations and the clinical condition may prove to be a challenge. An improved knowledge of the range of associated conditions that exist in people with DSD not only will help with interpreting the results of the genetic analyses but also will aid with the management of the affected patient.

Although a link between DSD and associated anomalies is recognized ([@B1]), it is generally thought that conditions such as hypospadias are rarely associated with abnormalities beyond the genitourinary system ([@B8]). Given the rarity of DSD, it has been difficult to ascertain the frequency and nature of associated anomalies in these cases. The Consensus Guidelines on DSD published in 2006 stressed the need for the creation and maintenance of a database in centers of expertise ([@B9]). Such databases do exist in many regional and national centers and have provided valuable insights into many aspects of DSD, including epidemiology ([@B1]), etiology ([@B10], [@B11]), variation of disease expression ([@B12]), initial adjustment of parents to their affected child\'s condition ([@B13]), and long-term outcome ([@B14]). However, as these databases and registries lacked uniformity, an international DSD (I-DSD) registry that collects information on cases with a range of conditions has now been in operation to overcome these issues ([@B15]). We have used this model of international collaboration to report on the largest cohort of cases of DSD that has been studied for associated anomalies.

Subjects and Methods
====================

Details of the I-DSD Registry, including its development and current operation, have been previously reported ([@B15], [@B16]) and are also available from its web site ([www.i-dsd.org](http://www.i-dsd.org)). Briefly, all clinicians belonging to recognized professional medical and scientific societies are eligible to register and report cases. This information is required when the clinician first registers as a user of the Registry. Users are then approved by the steering committee of the Registry before they can submit any cases. There are no restrictions on the age requirement of the case, with the Registry serving both adult and pediatric populations, and there is no time limit between initial presentation or diagnosis and entry into the Registry. Patient and/or parental consent must be obtained before case registration, with the level of consent tiered according to the extent to which the information may be shared (own center, own country, European Union member states, international). The I-DSD Registry is approved by the National Research Ethics Service of the United Kingdom.

The terminology used within the Registry is based on the nomenclature initially developed at the Chicago consensus meeting and which has continued to evolve subsequently ([@B9], [@B15]). In addition to details of diagnosis, the I-DSD Registry collects simple information on physical conditions that affect systems other than the reproductive system, as well as the occurrence of conditions such as small for gestational age (SGA), and short stature. See Supplemental Tables 1--4, published on The Endocrine Society\'s Journals Online web site at <http://jcem.endojournals.org>, for details of the data fields in the Registry.

At the time of the study in September 2012, there were 1050 cases submitted by registered clinicians from 20 centers in 14 different countries. Reporting clinicians for cases represented a range of specialties, including pediatric endocrinology, adult endocrinology, clinical genetics and biochemistry, and their countries of origin, are outlined in Supplemental Table 5. On analyzing the extracted data, 649 (62%) cases had a sufficient level of consent to allow sharing of suitable information. Anonymized data were obtained from the Registry regarding diagnosis, karyotype, sex of rearing, clinical center, genetic investigations, and any associated anomalies. Until September 2012, the field that captures "associated conditions" was labeled as "associated malformations." The field does not seek any further information on whether the associated condition is early onset, late onset, or acquired. Short stature in congenital adrenal hyperplasia was excluded from the analysis because this is a condition that is acquired as a consequence of the management of the disorder. Furthermore, the data were subanalyzed with the exclusion of cases where the condition was known to be associated with specific anomalies, namely P450 oxidoreductase deficiency (PORD), Müllerian duct aplasia, renal dysplasia, and cervical somite anomalies (MURCS), Mayer-Rokitansky-Küster-Hauser syndrome (MRKH), Turner syndrome, and 45,X/46,XY. Where information was unclear or incomplete, the reporting clinician was contacted to obtain further information.

Results
=======

Karyotype
---------

Of the 649 cases analyzed, 460 (71%), were 46,XY, 121 (19%) were 46,XX, 42 (6%) were 45,X/46,XY, 8 (1%) were 45,X, 6 (1%) were 46,XX/46,XY, 2 (0.3%) were 47,XXY, with other atypical karyotypes (such as translocations) making up the remaining 10 cases (1%). Of these cases with the respective karyotypes, associated conditions were reported in 6 cases of 45,X (75%), 19 cases of 45,X/46,XY (45%), 112 cases of 46,XY DSD (24%), 27 cases of 46,XX DSD (22%), and 4 cases with the atypical karyotypes (22%). Disorders of gonadal development occur in patients with a variety of karyotypes, and in the current cohort, of the 63 cases of a disorder of gonadal development with an associated condition, 33 (52%) were 46,XY, 3 (5%) were 46,XX, 5 (8%) were 45,X, 19 (30%) were 45,X/46,XY, 1 (2%) was 47,XXY, and 2 (2%) had an atypical karyotype.

Multiple conditions
-------------------

Of the 649 cases, associated conditions occurred in 168 (26%). Of these 168 cases, 103 (61%) cases had one condition each, 31 (18%) had two conditions, 20 (12%) had three conditions, and 14 (8%) had four or more conditions, with the maximum number being eight. Multiple conditions (more than one per case) were reported in 3 of 6 (50%) cases of 46,XX disorders of Müllerian development, 22 of 44 (50%) cases of nonspecific 46,XY DSD, 25 of 63 (40%) cases of disorders of gonadal development, 7 of 19 (37%) cases of disorders of androgen action, 3 of 11 (27%) cases of disorders of androgen excess, and 2 of 18 (11%) cases of disorders of androgen synthesis. Further details of the conditions encountered are outlined in [Table 1](#T1){ref-type="table"}.

###### 

Reported Anomalies According to Disorder Classification

  Disorder Type (number of accessible cases in Registry)   Number of Cases With Anomaly   Number of Cases With Each Type of Anomaly   Number of Cases With Anomaly by Karyotype                                                                         
  -------------------------------------------------------- ------------------------------ ------------------------------------------- ------------------------------------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ------------------
  Gonadal development (153)                                63                             1                                           3                                           9    9    7    4    4    14   17   4    5    19   7    \-   3    6    46,XY---33
                                                                                                                                                                                                                                                        46,XX---3
                                                                                                                                                                                                                                                        45,X---5
                                                                                                                                                                                                                                                        45,X/46, XY---19
                                                                                                                                                                                                                                                        47,XXY---1
                                                                                                                                                                                                                                                        Other---2
  Androgen synthesis (100)                                 18                             \-                                          \-                                          1    1    \-   \-   \-   \-   \-   \-   1    \-   13   1    \-   3    46,XY---9
                                                                                                                                                                                                                                                        46,XX---9
  Androgen action (172)                                    19                             \-                                          \-                                          3    1    \-   2    2    3    3    2    5    4    3    1    1    7    46,XY---19
  Androgen excess (75)                                     9                              \-                                          \-                                          1    1    \-   \-   1    1    2    \-   \-   \-   1    \-   1    5    46,XY---1
                                                                                                                                                                                                                                                        46,XX---8
  Nonspecific XY DSD (90)                                  44                             1                                           1                                           8    4    5    3    6    11   7    3    17   4    5    3    1    10   46,XY---44
  XX Müllerian devpt (12)                                  6                              \-                                          \-                                          1    \-   \-   1    \-   1    6    \-   \-   \-   2    \-   1    \-   46,XX---6
  PMDS (5)                                                 1                              \-                                          \-                                          \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    46,XY---1
  Leydig cell defects (17)                                 1                              \-                                          \-                                          1    1    \-   1    \-   \-   \-   \-   \-   \-   1    1    \-   \-   46,XY---1
  Other (25)                                               7                              1                                           \-                                          3    \-   \-   \-   \-   2    \-   \-   \-   1    \-   \-   1    1    46,XY---5
                                                                                                                                                                                                                                                        46,XX---1
                                                                                                                                                                                                                                                        45,X---1
  Total (649)                                              168                            3                                           4                                           27   17   12   11   13   32   35   9    28   28   32   6    8    33   

Abbreviation: PMDS, persistent Müllerian duct syndrome. Dashes indicate no cases recorded.

Range of conditions
-------------------

The range and distribution of associated conditions differed substantially between cases of 46,XY and 46,XX DSD ([Figure 1](#F1){ref-type="fig"}). SGA was reported in 26 of 112 cases (23%) of 46,XY DSD with associated conditions; however, there were no cases of SGA in the 46,XX DSD group. Central nervous system (CNS) and cardiac conditions were next most frequent in 46,XY DSD, each reported in 22 of the 112 cases (20%) of 46,XY DSD with associated conditions.

![Range of anomalies reported in 46,XX and 46,XY DSD.](zeg9991304820001){#F1}

In the 90 cases of nonspecific XY DSD without any clear diagnosis on the registry, 17 (19%) were reported to be SGA, 11 (12%) had cardiac abnormalities, and 8 (9%) had involvement of the CNS ([Table 1](#T1){ref-type="table"}). In the 153 cases of disorders of gonadal development on the registry, 19 (12%) had short stature (15 of which occurred in cases with 45,X or 45,X/46,XY karyotype, 3 in cases of 46,XY DSD, and 1 case with an atypical karyotype), 17 (11%) had renal anomalies (7 of which occurred in cases with 45,X or 45,X/46,XY karyotype), and 14 (9%) had cardiac abnormalities (6 of which occurred in cases with 45,X or 45,X/46,XY karyotype) ([Table 1](#T1){ref-type="table"}).

Conditions affecting the skeleton were present in 12 of 27 (44%) cases of 46,XX DSD with an associated condition and these cases included two cases of MURCS, diagnosed clinically, seven cases of PORD all with genetic confirmation of diagnosis, two unconfirmed nonclassical 3β-hydroxysteroid dehydrogenase deficiency, and one case of 11β-hydroxylase deficiency, with genetic confirmation. Conditions involving renal development were encountered in 8 of the 27 cases (30%) and were commonest in those with a 46,XX disorder of Müllerian development, occurring in 6 of 12 cases in the Registry (50%), and present in all such cases that had an anomaly recorded.

As associated conditions are already known to occur in some syndromes associated with DSD, 8 cases of Turner syndrome, 42 cases of 45,X/46,XY, 19 cases of PORD, and 12 cases of Müllerian development anomalies were excluded from the overall 649 cases. Of the remaining 568 cases, 127 (22%) had an associated condition that did not form a recognized part of the disorder. Of these 127, 108 (85%) were 46,XY, 15 (12%) were 46,XX, 2 (2%) had a nonsex chromosome rearrangement, and there was 1 case each (1%) of 46,XX/46,XY and 47,XXY, respectively. Of these 127 cases, 75 (60%) had one condition, 22 (17%) had two conditions, 18 (14%) had three conditions, and 12 (9%) had four or more conditions, with the maximum number of conditions encountered in one patient being eight. Among these 127 cases there were 44 cases of nonspecific 46,XY DSD, 39 cases of disorders of gonadal development, 19 cases of disorders of androgen action, 10 case of disorders of androgen synthesis, 9 cases of disorders of androgen excess, 1 case each of Leydig cell defects and persistent Müllerian duct syndrome, and 6 cases classified as "other" disorders. Of the 39 cases of disorders of gonadal development, 10 (26%) had a renal condition, 8 (21%) had a cardiac condition, 8 (21%) had a CNS condition, 8 (21%) had a craniofacial disorder, 4 each (10%) had short stature, ear, nose, and throat, gastrointestinal (GI) tract, respiratory or skeletal conditions, 3 (8%) had blood and lymph conditions, eye conditions, SGA, or an unidentified syndrome, and 1 (3%) had an adrenal condition.

The pattern and frequency of anomalies also varied between 46,XY and 46,XX DSD after exclusion of the syndromic DSD conditions ([Figure 2](#F2){ref-type="fig"}). Of the 451 cases of 46,XY DSD, an associated condition was reported in 108 (24%) and in 15 of 98 cases (15%) of 46,XX DSD. In 46,XY DSD, SGA was the most frequent condition in 26 cases (24%), with cardiac anomalies in 22 cases (20%) and CNS conditions in 21 cases (19%). In 46,XX DSD, there was an even spread of conditions with the most frequent condition being skeletal occurring in 3 of 15 cases (20%).

![Range of anomalies reported after exclusion of known DSD syndromic associations in 46,XX and 46,XY DSD.](zeg9991304820002){#F2}

Monogenic DSD
-------------

Of 170 cases reported as androgen insensitivity syndrome (AIS), 19 (11%) were recorded as having an associated condition. Of these 19 cases, 9 had a confirmed androgen receptor mutation, occurring in six cases of Complete AIS and three cases of Partial AIS. Associated conditions were reported to affect the renal system in two cases, skeleton in one case, skin in one case, CNS in one case, GI tract in one case, heart in one case, and an unspecified condition in five cases ([Table 2](#T2){ref-type="table"}). Associated conditions were also reported in 8 of 72 (11%) cases of 21α-hydroxylase deficiency (1 of which had confirmed CYP21A2 mutation, while the remainder were diagnosed clinically), 4 of 26 (15%) cases of 17β-hydroxysteroid dehydrogenase type 3 deficiency (all with confirmed HSD17B3 mutation), and 2 of 19 cases (10%) of 5α-reductase type 2 deficiency. In the 8 cases of 21α-hydroxylase deficiency, two had renal conditions. In the remainder, there was one case of a CNS condition, one affecting the GI tract, and one case each detailed as severe autism, spastic paraplegia, polyarthritis, learning disability, and one not specified.

###### 

Reported Anomalies in Monogenic Conditions

  Disorder                                                                 Total Number   Number Cases With Anomaly   CNS   Number of Cases With Each Anomaly                                                     
  ------------------------------------------------------------------------ -------------- --------------------------- ----- ----------------------------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  Disorders of androgen synthesis                                                                                                                                                                                 
      17βhydroxysteroid dehydrogenase type 3 deficiency                    26             4                           1     \-                                  \-   \-   \-   \-   \-   \-   \-   1    \-   \-   3
      5α reductase type 2 deficiency                                       19             2                           \-    \-                                  \-   \-   \-   \-   \-   1    \-   \-   1    \-   \-
      P450 oxidoreductase deficiency                                       19             10                          \-    1                                   \-   \-   \-   \-   \-   \-   \-   10   \-   \-   \-
  Disorder of androgen action                                                                                                                                                                                     
      Complete androgen insensitivity syndrome (AR mutation +ve)           77             6                           1     \-                                  \-   1    1    1    \-   \-   \-   \-   1    \-   3
      Complete androgen insensitivity syndrome (AR mutation −ve/unknown)   16             3                           \-    \-                                  \-   \-   \-   1    \-   \-   \-   1    \-   \-   1
      Partial androgen insensitivity syndrome (AR mutation +ve)            39             3                           \-    \-                                  \-   \-   \-   1    \-   \-   \-   1    \-   \-   2
      Partial androgen insensitivity syndrome (AR mutation −ve)            38             7                           2     1                                   2    1    2    \-   2    5    4    1    \-   1    1
  Disorder of androgen excess                                                                                                                                                                                     
      21αHydroxylase deficiency                                            72             8                           1     \-                                  \-   1    1    2    \-   \-   \-   \-   \-   \-   5
      11βHydroxysteroid dehydrogenase deficiency                           1              1                           \-    1                                   \-   \-   \-   \-   \-   \-   \-   1    \-   1    \-

Abbreviation: AR, androgen receptor. Two cases reported as possible nonclassic 3β-hydroxysteroid dehydrogenase have been included in [Table 1](#T1){ref-type="table"} as androgen synthesis disorders, but due to diagnostic uncertainty have not been included in the monogenic conditions in [Table 2](#T2){ref-type="table"}. Two cases described as "disorders of androgen excess" have the diagnosis "other" with no confirmed diagnosis and are therefore not included in [Table 2](#T2){ref-type="table"}. Dashes indicate no cases recorded.

Discussion
==========

The results from this analysis of the I-DSD Registry reveal that associated conditions are frequent in DSD, with a rate of 27%, which is over 10 times the birth prevalence of congenital anomalies ([@B17]). This is not unexpected, given that the presence of one congenital condition is known to be associated with the presence of further anomalies because disrupting factors, whether environmental or genetic, are likely to affect multiple developmental processes. Furthermore, approximately 10% of the cases of DSD had more than one associated condition, highlighting the need for input from multiple specialists. When cases with DSD syndromes and chromosomal anomalies were excluded, the overall frequency of associated conditions was similar to the overall cohort. These figures are also in keeping with the findings of an epidemiological study carried out in Germany that identified a higher rate of 37.5% for associated malformations in infants with ambiguous genitalia ([@B18]).

Although the ranges of anomalies that are encountered are different, it is of interest that in the current cohort of cases in the I-DSD Registry, the reported prevalence of associated conditions in 46,XY and 46,XX DSD at 24% and 22% was similar. With the exclusion of the cases that are well known to be associated with anomalies, the prevalence of associated conditions in the other cases of 46,XY and 46,XX DSD was 24% and 15%, respectively. The type of conditions encountered in 45,X/46,XY cases bears a striking resemblance to the known phenotype in Turner syndrome, with partial or complete gonadal dysgenesis. This is reflected in the high frequency of associated conditions in all cases with gonadal dysgenesis. Our findings echo the description of the 45,X/46,XY phenotype by Tosson et al and Telvi et al ([@B19], [@B20]) and the cardiac phenotype refined by De Groote et al ([@B21]). These findings highlight the importance of a thorough screening for associated conditions in both male and female individuals with this karyotype.

It has long been recognized that there is a strong association between SGA and DSD ([@B1], [@B22]), and this was reflected in our findings. It was notable that there were no reported cases of SGA in 46,XX DSD. It has been speculated that altered prenatal androgen exposure may alter in utero growth but this is debatable ([@B23], [@B24]). An alternative hypothesis for the origins of low birth weight in 46,XY DSD is that both are the result of early placental insufficiency ([@B25], [@B26]) and this requires further investigation.

In 46,XX DSD, an association with skeletal and renal anomalies is recognized in conditions such as MURCS, MRKH, and PORD ([@B7], [@B27]). This was borne out by our results, in which renal conditions were common in women with 46,XX DSD and disorders of Müllerian development. Similarly, skeletal involvement was also observed in women with 46,XX DSD and PORD or MURCS. Renal disorders are also a recognized feature of 46,XY DSD due to the Denys Drash and WAGR (Wilms, Aniridia, Genitourinary anomalies, mental Retardation) syndromes. Furthermore, bone and kidney abnormalities combined with genital anomalies are a component of Smith-Lemli-Opitz syndrome ([@B28]). Renal tract anomalies have previously been reported as occurring in 14 of 66 females (21%) with congenital adrenal hyperplasia ([@B29]) and were also confirmed to be present in the current cohort occurring in two cases of 21α-hydroxylase deficiency. When recognized associations were excluded from the analysis, renal and skeletal disorders were still encountered in up to 4% of cases of 46,XX DSD and 46,XY DSD.

The unexpected presence of renal abnormalities in AIS cases with a confirmed androgen receptor mutation raises a question about the developmental role of the androgen receptor in the kidney. Previously, an association between Complete AIS and renal anomalies has been described in one case ([@B30]). In mice, the kidney is one of the most androgen sensitive, nonreproductive organs, with a close correlation between kidney mass and androgen levels in the male ([@B31]). In addition, several developmental genes are known to be androgen-regulated in the mouse ([@B32]). Our finding of two cases with renal anomalies in congenital adrenal hyperplasia is also worthy of emphasis, as it highlights the importance of thorough investigation of the whole renal tract in such patients. Ten cases reported as AIS without a confirmed androgen receptor mutation had an associated condition. Of these, five cases had SGA and four had short stature. Given that these associations are often encountered in cases of gonadal dysgenesis, these cases of presumed AIS need a thorough investigation of gonadal function.

It is possible that some of the associations revealed by our analysis of the Registry may represent co-occurrence of anomalies by chance. Renal tract anomalies have been reported as occurring with a frequency of 25 per 1000 in the general European population ([@B17]). This compares to a frequency in our analysis of 35 of 649, equivalent to 54 per 1000. The frequency of cardiac anomalies, the second most common anomaly in our population, is reported as 8 per 1000 in the European population ([@B33]). This compares to the occurrence of cardiac anomalies in our analysis of 32 of 649, equivalent to 49 per 1000.

The I-DSD Registry is not an epidemiological registry and, as it does not collect information on all cases of DSD, it may suffer from a reporting and selection bias. It is recognized that there may be a bias toward the reporting of more clinically unusual cases, which could increase the reported prevalence of anomalies. Registry users can also choose the extent of data sharing with other users for each individual case and this sharing may depend on the patient\'s or clinician\'s preference. Based on the access level of the investigators, only 60% of the cases in the Registry could be accessed for this study and this may have also introduced some selection bias. However, the similarities between our results and the findings of a national study suggest that the prevalence figure of 25% for associated conditions probably is representative of the true prevalence ([@B18]). In particular, cases of congenital adrenal hyperplasia may be underrepresented in the Registry due to reporting methods, given that the incidence in the general population is estimated at around 1 in 15 000 live births ([@B34]). The incidence of AIS was described in a Danish population registry as 1 in 20 400 ([@B35]), whereas MRKH is estimated as occurring in 1 in 4500 females ([@B36]). However, the Registry does not necessarily represent the population prevalence of these disorders because it relies on clinician reporting rather that population screening.

All data are self-recorded by the clinician, with little recourse to source verification of entered data, and it can be difficult in such a registry to be clear that all users have the same understanding of an associated condition that is congenital. It is also possible that some congenital conditions may not be manifested until a later age. Until recently, the data collection form asked investigators to enter data on "associated malformations," which implies congenital conditions. More recently, the term "malformations" has been replaced by the term "conditions." It would be beneficial in future revisions of the Registry to provide some explanatory data to ensure that conditions that are considered to be of congenital and those considered to be acquired are captured separately and there may be additional value in assessing the age of onset of the manifestation of the condition.

However, the use of an international registry of such rare conditions in such a large group of cases has, nevertheless, pointed to some new associations in DSD and the study highlights the strength of a global effort to collect data in rare diseases, which will encourage reporting of more cases of DSD with associated conditions. In conclusion, we have found that, in this cohort of cases, associated anomalies are reported in around a quarter of cases of DSD. The prevalence of associated conditions is much greater in disorders of gonadal development and nonspecific 46,XY DSD. In 46,XY DSD, the largest group of cases in the Registry, the commonest associated conditions included SGA, cardiac, and CNS. In many cases of DSD the etiology remains obscure and the current findings may lead to new research targets as well as improved care of those affected by these disorders.
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